Abstract

IntroductionThe quadrivalent HPV vaccine is highly effective in primary prevention of anogenital warts (AGWs). However, there is lack of systematic review in the literature of the epidemiology of AGWs in Sub Saharan Africa (SSA).ObjectiveTo review the prevalence, incidence and risk factors for AGWs in SSA prior to the introduction of HPV vaccination programs.MethodsPubMed/MEDLINE, Africa Index Medicus and HINARI websites were searched for peer reviewed English language published medical literature on AGWs from January 1, 1984 to June 30, 2012. Relevant additional references cited in published papers were also evaluated for inclusion. For inclusion, the article had to meet the following criteria (1) original studies with estimated prevalence and/or incidence rates among men and/or women (2) detailed description of the study population (3) clinical or self-reported diagnosis of AGWs (4) HPV genotyping of histologically confirmed AGWs. The final analysis included 40 studies. Data across different studies were synthesized using descriptive statistics for various subgroups of females and males by geographical area. A meta - analysis of relative risk was conducted for studies that had data reported by HIV status.ResultsThe prevalence rates of clinical AGWs among sex workers and women with sexually transmitted diseases (STDs) or at high risk of sexually transmitted infection (STIs) range from 3.3% - 10.7% in East, 2.4% - 14.0% in Central and South, and 3.5% - 10.5% in West African regions. Among pregnant women, the prevalence rates range from 0.4% - 3.0% in East, 0.2% - 7.3% in Central and South and 2.9% in West African regions. Among men, the prevalence rates range from 3.5% - 4.5% in East, 4.8% - 6.0% in Central and South and 4.1% to 7.0% in West African regions. In all regions, the prevalence rates were significantly higher among HIV+ than HIV- women with an overall summary relative risk of 1.62 (95% CI: 143–1.82).The incidence rates range from 1.1 – 2.7 per 100 person-years among women and 1.4 per 100 person years among men. Incidence rate was higher among HIV+ (3.0 per 100 person years) and uncircumcised men (1.7 per 100 person-years) than circumcised men (1.3 per 100 person-years).HIV positivity was a risk factor for AGWs among both men and women. Other risk factors in women include presence of abnormal cervical cytology, co-infection with HPV 52, concurrent bacteria vaginoses and genital ulceration. Among men, other risk factors include cigarette smoking and lack of circumcision.ConclusionsAGWs are common among selected populations particularly HIV infected men and women. However, there is need for population-based studies that will guide policies on effective prevention, treatment and control of AGWs.

Highlights

  • The quadrivalent HPV vaccine is highly effective in primary prevention of anogenital warts (AGWs)

  • The prevalence and incidence rates of AGWs in diverse female and male hospital-based study populations in East, Central and South, and West African regions is summarized in Tables 1, 2 and 3

  • There is interand intra-region variations in rates depending on the underlying prevalence rate of HIV-1 infection, study population and age group studied

Read more

Summary

Introduction

The quadrivalent HPV vaccine is highly effective in primary prevention of anogenital warts (AGWs). The epidemiology of AGWs in most of SSA is largely unknown since few studies have been conducted. Caused mainly by low-risk HPV type 6 and 11, AGWs affect both men and women [1]. They are highly infectious with about 65% of individuals with an infected partner developing lesions within 3 weeks [4]. AGWs have been associated with malignant Bushke-Lowenstein malignant tumors [8]. Their occurrence is strongly linked to HIV and weakly associated with cigarette smoking [1,4,5]. The impact of highly active anti-retroviral therapy (HAART) remains unclear [5,6]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.